Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.

Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E.

J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200/JCO.2008.17.6644.

2.

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group.

Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC.

Clin Cancer Res. 2010 Jan 15;16(2):750-4. doi: 10.1158/1078-0432.CCR-09-1906.

3.

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.

Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8.

4.

A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, Fouts ME, Medina D, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2008 Feb 15;14(4):1111-5. doi: 10.1158/1078-0432.CCR-07-4097.

5.

A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.

Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, Kromplewski M, Fouts ME, Medina D, Cho SY, Cohn SL, Krivoshik A, Hagey AE, Adamson PC, Balis FM.

Clin Cancer Res. 2006 Aug 15;12(16):4882-7.

6.

Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.

Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T.

Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8.

PMID:
17594093
7.

A phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancer.

Roché H, De Benedictis E, Cottura E, Govi S, Dalenc F, Locatelli A, Deslandres M, Zambetti M, Gladieff L, Messina M, Gianni L.

Clin Breast Cancer. 2012 Jun;12(3):167-74. doi: 10.1016/j.clbc.2012.03.009.

PMID:
22607766
8.

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas.

Aghajanian C, Burris HA 3rd, Jones S, Spriggs DR, Cohen MB, Peck R, Sabbatini P, Hensley ML, Greco FA, Dupont J, O'Connor OA.

J Clin Oncol. 2007 Mar 20;25(9):1082-8.

PMID:
17261851
9.

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.

Fox E, Aplenc R, Bagatell R, Chuk MK, Dombi E, Goodspeed W, Goodwin A, Kromplewski M, Jayaprakash N, Marotti M, Brown KH, Wenrich B, Adamson PC, Widemann BC, Balis FM.

J Clin Oncol. 2010 Dec 10;28(35):5174-81. doi: 10.1200/JCO.2010.30.9674.

10.

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy.

Awada A, Piccart MJ, Jones SF, Peck RA, Gil T, Lebwohl D, Wu CY, Burris HA 3rd.

Cancer Chemother Pharmacol. 2009 Feb;63(3):417-25. doi: 10.1007/s00280-008-0751-5.

PMID:
18446338
11.

A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.

Peereboom DM, Supko JG, Carson KA, Batchelor T, Phuphanich S, Lesser G, Mikkelsen T, Fisher J, Desideri S, He X, Grossman SA; New Approaches to Brain Tumor Therapy (NABTT) Consortium..

J Neurooncol. 2010 Nov;100(2):261-8. doi: 10.1007/s11060-010-0190-0. Erratum in: J Neurooncol. 2010 Nov;100(2):269. Mikkelson, Tom [corrected to Mikkelsen, Tom].

12.

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, Widemann B, Davis L, Damle B, Sonnichsen D, Lebwohl D, Bates S, Kotz H, Fojo T.

J Clin Oncol. 2003 May 1;21(9):1866-73.

PMID:
12721265
13.

Phase 1 trial and pharmacokinetic study of the oral platinum analog satraplatin in children and young adults with refractory solid tumors including brain tumors.

Akshintala S, Marcus L, Warren KE, Murphy RF, Sissung TM, Srivastava A, Goodspeed WJ, Goodwin A, Brewer CC, Zalewski C, King KA, Kim A, Figg WD, Widemann BC.

Pediatr Blood Cancer. 2015 Apr;62(4):603-10. doi: 10.1002/pbc.25344.

14.

Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group.

Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC; Children's Oncology Group..

J Clin Oncol. 2007 Apr 20;25(12):1505-11. Erratum in: J Clin Oncol. 2008 Jan 1;26(1):165.

PMID:
17442992
15.

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P, Rutt A, Balis FM, Bates S, Fojo T.

Cancer. 2005 May 1;103(9):1932-8.

16.

A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.

Plummer R, Woll P, Fyfe D, Boddy AV, Griffin M, Hewitt P, Carmichael J, Namouni F, Cohen M, Verrill M.

Clin Cancer Res. 2008 Dec 15;14(24):8288-94. doi: 10.1158/1078-0432.CCR-08-0471.

17.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.

Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL.

Invest New Drugs. 2012 Dec;30(6):2364-70. doi: 10.1007/s10637-012-9800-3.

18.

Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study.

Langevin AM, Casto DT, Thomas PJ, Weitman SD, Kretschmar C, Grier H, Pratt C, Dubowy R, Bernstein M, Blaney S, Vietti T.

J Clin Oncol. 1998 Jul;16(7):2494-9.

PMID:
9667269
19.

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.

Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM.

J Clin Oncol. 2006 Jan 20;24(3):507-16.

PMID:
16421428
20.

Phase I trial of dasatinib and ixabepilone in patients with solid tumors.

Herbolsheimer P, Kapoor R, Smith KL, Perry D, Verma N, Veytsman I, Jelinek J, Swain SM.

Invest New Drugs. 2013 Feb;31(1):92-8. doi: 10.1007/s10637-012-9805-y.

PMID:
22392508

Supplemental Content

Support Center